Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

2.020 +0.140 (+7.45%)
Streaming Delayed Price Updated: 2:16 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based 
Via PressReach
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based 
Via PressReach
Uncovering Potential: BioRestorative Therapies's Earnings Preview
Via Benzinga
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Earnings Preview For BioRestorative Therapies
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Scheduled For May 14, 2025
Via Benzinga
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies
Via TheNewswire.com
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
By Meg Flippin Benzinga 
Via TheNewswire.com
Exposures Product Safety
Which stocks have an unusual volume on Thursday?
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
Earnings Scheduled For March 27, 2025
Via Benzinga
On Tuesday, there are stocks with unusual volume. Let's take a look.
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial
BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial 
Via News Direct
Topics Intellectual Property
Exposures Intellectual Property
Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market
Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market 
Via News Direct
Topics Intellectual Property
Exposures Intellectual Property
BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function
BioRestorative Therapies shares promising Phase 2 trial results for BRTX-100, showing significant pain reduction and functional improvement in cLDD patients. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?
Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind? 
Via News Direct
Topics Intellectual Property
Exposures Intellectual Property
BRTX Stock Earnings: BioRestorative Therapies Beats EPS, Beats Revenue for Q2 2024
BRTX stock results show that BioRestorative Therapies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
What's Going On With BioRestorative Therapies Stock?
BioRestorative Therapies shares are trading higher Monday after the company announced it has received notice from the Nasdaq Stock Market that it has regained compliance with listing requirements. 
Via Benzinga
S&P 500 Edges Higher; J.Jill Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Gold Down 1%; Broadcom Shares Jump After Upbeat Results
Via Benzinga
Why BioRestorative Therapies Stock Is Moving Higher Thursday
BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with a regenerative medicine company related to its ThermoStem Metabolic... 
Via Benzinga
Why Is Sharps Technology (STSS) Stock Up 21% Today?
Sharps Technology stock is up on Thursday with heavy trading of STSS shares after the company signed a $30 million purchase order. 
Via InvestorPlace
Why Is BioRestorative Therapeutics (BRTX) Stock Up 42% Today?
BioRestorative Therapeutics stock is up on Thursday with heavy trading of BRTX shares after announcing licensing negotiations. 
Via InvestorPlace
Dow Tumbles Over 100 Points; US Producer Prices Decline In May
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.